Finally, ARIEL 4 (NCT02855944) is an ongoing phase III study, which was designed to compare the efficacy and the safety of rucaparib versus physician’s choice of chemotherapy, depending on platinum status, in BRCA1/2 mutated recurrent ovarian cancer following at least two previous lines of systemic treatment [41]. The gene discussed is BRCA1; the disease is ovarian carcinoma.